Full Press Release Details
Announcements Office
Australian Securities Exchange
Notice under Section 708A(5)(e) Corporations Act
On 15th May 2015, Prima BioMed Ltd ( the Company ) issued 22,936,950 fully paid ordinary
shares in accordance with the terms of its Share Purchase and Convertible Security Agreement with Bergen Global Opportunity Fund, LP, which was announced to the market on 2nd October 2014 and
issued 72,206,500 fully paid ordinary shares to Ridgeback Capital Investments, under the terms which were announced to the market on 14th May 2015.
Accordingly the Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act ) that:
(a) the provisions of Chapter
2M Corporations Act as they apply to the Company; and
(b) section 674 Corporations Act; and
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889